Doximity (DOCS) Q1 2027 Earnings Call Transcript

Doximity reported Q1 2027 revenue of $156.6M (+7% YoY) and adjusted EBITDA of $74.8M (48% margin), beating the high end of guidance, while raising full-year 2027 revenue guidance by $6M to $671M–$681M. AI usage accelerated materially (AI prompt volume +25% QoQ; AI Scribe users up 10x in July; quarterly active workflow prescribers +30% YoY), with nearly 50% of prescribers using AI tools and 165 signed health system clients. Profitability remained resilient despite higher AI compute spending (non-GAAP gross margin 87.5% vs 91.2% prior year), and the company continued buybacks ($91.6M in the quarter; ~$400M remaining authorization) on a debt-free balance sheet with $688M cash and marketable securities.

Analysis

DOCS is transitioning from a legacy pharma-marketing platform into a workflow layer for clinician AI, which changes the competitive frame. The near-term winner is not just DOCS itself but any vendor that can monetize enterprise trust, privacy, and embedded workflow; that likely means hospital IT buyers and secure data-layer providers, while generic consumer-grade clinical AI models face slower adoption in regulated settings. The second-order effect is budget reallocation: AI search is pulling spend from pharma brand marketing and some hospital point solutions, so the loser set may include weaker scribe/clinical-decision-support vendors and ad-tech middlemen that lack a compliance story.

The market will likely overreact to the current-quarter usage surge but underappreciate the lag between engagement and durable contract value. In the next 1-3 months, the key catalyst is whether early AI contracts expand from capped trial inventory into longer upfront commitments; if they do, revenue inflects faster than consensus. Over 6-18 months, the real question is gross margin durability: compute costs and SBC can keep headline EBITDA strong while free cash flow and GAAP optics remain noisy. Falsifier: if AI search revenue fails to show material contribution by Q3, or if gross margin stays stuck in the mid-80s without operating leverage, the AI thesis de-rates.

Contrarian view: the bullish consensus is treating model accuracy as a moat, but the deeper moat is distribution into hospital workflows. If EHR vendors or large incumbents bundle similar tools at low incremental cost, DOCS may win safety headlines but lose pricing power. That argues for staying long the stock only on pullbacks or via call spreads, not chasing after an earnings pop.

Key Decisions for Investors

• Long DOCS on post-earnings weakness over the next 1-2 weeks; target a 3-6 month hold. Thesis is that AI search converts from engagement story to revenue story in Q3, with upside if upfront contracts expand. Falsify if Q3 AI revenue contribution is immaterial or gross margin compresses further.
• Pair trade: long DOCS / short TDOC for 3-6 months. DOCS has better enterprise distribution, stronger balance sheet, and clearer AI monetization path; TDOC is more exposed to commoditization and lower trust in clinical workflows. Exit if DOCS loses enterprise share or TDOC shows a materially better AI product rollout.
• Use DOCS call spreads instead of outright equity if chasing momentum: buy 3-6 month call spreads funded on strength after the print. Risk/reward is attractive if AI search revenue is recognized in Q3, but downside is limited if adoption stalls.
• Watch item: if hospital AI steering committee adoption accelerates faster than pharma budget conversion, consider adding on any selloff tied to 'budget tightness' headlines. The hospital side can be a lower-cost replacement trade, which may expand adoption even if pharma remains soft.